drugset / Trial / NCT00316030

Study of Bexarotene in Patients With Acute Myeloid Leukemia

NCT00316030

Phase 1 Completed 54 enrolled Abramson Cancer Center at Penn Medicine
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Bexarotene may be useful in the treatment of Acute Myeloid Leukemia (AML). This is the first study on the use of bexarotene to treat patients with AML. The main purpose of this study is to establish the proper dose of bexarotene when used to treat AML. The side effect profile of bexarotene in patients with AML will also be explored.

Timeline

Start
2004-01
Primary completion
Completion

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bexarotene Small molecule Oral